Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 139, Issue 3, 2007, Pages 398-404

  Maddocks Christianson, Kami ^a   Slager, Susan L ^a   Zent, Clive S ^a   Reinalda, Megan ^a   Call, Timothy G ^a   Habermann, Thomas M ^a   Bowen, Deborah A ^a   Hoyer, James D ^a   Schwager, Susan ^a   Jelinek, Diane F ^a   Kay, Neil E ^a   Shanafelt, Tait D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic lymphocytic leukaemia; Lymphoma; Prognostic parameters; Transformation; Treatment

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HODGKIN DISEASE; HUMAN; LYMPHOCYTE COUNT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; T CELL LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PURINE NUCLEOTIDES; RISK FACTORS; VIDARABINE;

EID: 34848904482     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06801.x     Document Type: Article

References (43)

1. Abruzzo, L.V., Rosales, C.M., Medeiros, L.J., Vega, F., Luthra, R., Manning, J.T., Keating, M.J. Jones, D. (2002) Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. American Journal of Surgical Pathology, 26, 630 636.
2. Armitage, J.O., Dick, F.R. Corder, M.P. (1978) Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia. Cancer, 41, 422 427.
3. Bartik, M.M., Welker, D. Kay, N.E. (1998) Impairments in immune cell function in B cell chronic lymphocytic leukemia. Seminars in Oncology, 25, 27 33.
4. Bosch, F., Crespo, M., Villamor, N., Muntanola, A., Ferrer, A., Domingo, A., Rozman, M., Rozman, C., Lopez-Guillermo, A. Montserrat, E. (2004) Clinical characteristics and outcome of a large series of patients with chronic lymphocytic leukemia (CLL) according to ZAP-70 expression. Blood, 104, (Abstract)14.
5. Call, T.G., Phyliky, R.L., Noel, P., Habermann, T.M., Beard, C.M., O'Fallon, W.M. Kurland, L.T. (1994) Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clinic Proceedings, 69, 323 328.
6. Cheson, B.D., Vena, D.A., Barrett, J. Freidlin, B. (1999) Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. Journal of Clinical Oncology, 17, 2454 2460.
7. Cingolani, A., Gastaldi, R., Fassone, L., Pierconti, F., Giancola, M.L., Martini, M., De Luca, A., Ammassari, A., Mazzone, C., Pescarmona, E., Gaidano, G., Larocca, L.M. Antinori, A. (2000) Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. Journal of Clinical Oncology, 18, 3325 3330.
8. Dewald, G.W., Brockman, S.R., Paternoster, S.F., Bone, N.D., O'Fallon, J.R., Allmer, C., James, C.D., Jelinek, D.F., Tschumper, R.C., Hanson, C.A., Pruthi, R.K., Witzig, T.E., Call, T.G. Kay, N.E. (2003) Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 121, 287 295.
9. Fayad, L., Robertson, L.E., O'Brien, S., Manning, J.T., Wright, S., Hagemeister, F., Cabanillas, F. Keating, M.J. (1996) Hodgkin's disease variant of Richter's syndrome: experience at a single institution. Leukemia and Lymphoma, 23, 333 337.
10. Giles, F.J., O'Brien, S.M. Keating, M.J. (1998) Chronic lymphocytic leukemia in (Richter's) transformation. Seminars in Oncology, 25, 117 125.
11. Hamblin, T.J., Jones, J.V. Peacock, D.B. (1975) The immune response to phichi174 in man. IV. Primary and secondary antibody production in patients with chronic lymphatic leukaemia. Clinical and Experimental Immunology, 21, 101 108.
12. Hopwood, P. Crawford, D.H. (2000) The role of EBV in post-transplant malignancies: a review. Journal of Clinical Pathology, 53, 248 254.
13. Jelinek, D.F., Tschumper, R.C., Geyer, S.M., Bone, N.D., Dewald, G.W., Hanson, C.A., Stenson, M.J., Witzig, T.E., Tefferi, A. Kay, N.E. (2001) Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. British Journal of Haematology, 115, 854 861.
14. Jelinek, D.F., Tschumper, R.C., Stolovitzky, G.A., Iturria, S.J., Tu, Y., Lepre, J., Shah, N. Kay, N.E. (2003) Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Molecular Cancer Research, 1, 346 361.
15. Johnson, S., Smith, A.G., Löffler, H., Osby, E., Juliusson, G., Emmerich, B., Wyld, P.J., Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet, 347, 1432 1438.
16. Kanzler, H., Kuppers, R., Helmes, S., Wacker, H.H., Chott, A., Hansmann, M.L. Rajewsky, K. (2000) Hodgkin and Reed-Sternberg-like cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood, 95, 1023 1031.
17. Keating, M.J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L.E., Freireich, E.J., Estey, E. Kantarjian, H. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92, 1165 1171.
18. Koduru, P.R., Lichtman, S.M., Smilari, T.F., Sun, T., Goh, J.C., Karp, L., Hall, W., Hashimoto, S., Chiorazzi, N. Broome, J.D. (1993) Serial phenotypic, cytogenetic and molecular genetic studies in Richter's syndrome: demonstration of lymphoma development from the chronic lymphocytic leukaemia cells. British Journal of Haematology, 85, 613 616.
19. Lazzarino, M., Orlandi, E., Baldanti, F., Furione, M., Pagnucco, G., Astori, C., Arcaini, L., Viglio, A., Paulli, M., Gerna, G. Bernasconi, C. (1999) The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. British Journal of Haematology, 107, 877 882.
20. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 2319 2325.
21. Mauro, F.R., Foa, R., Giannarelli, D., Cordone, I., Crescenzi, S., Pescarmona, E., Sala, R., Cerretti, R. Mandelli, F. (1999) Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood, 94, 448 454.
22. Morrison, V.A., Rai, K., Peterson, B.L., Kolitz, J., Elias, L., Hines, J., Shepherd, L., Larson, R.A. Schiffer, C.A. (1999) Transformation to Richter's syndrome or prolymphocytic leukemia (PLL), and other second hematologic malignancies in patients with chronic lymphocytic leukemia (CLL). Blood, 94, Abstract no. 2410.
23. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. Linet, M.S. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 265 276.
24. Nakamura, N. Abe, M. (2003) Richter syndrome in B-cell chronic lymphocytic leukemia. Pathology International, 53, 195 203.
25. Pocock, C., Matutes, E., Wotherspoon, A.C., Cunningham, D. Catovsky, D. (1998) Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukemia but not in follicular lymphoma. Blood, 92 (Suppl. 1 429a, Abstract no. 1774.
26. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1750 1757.
27. Richter, M. (1928) Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. American Journal of Pathology, 4, 285 292.
28. Robak, T. (2004) Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology, 9, 387 400.
29. Robak, T., Blonski, J.Z., Gora-Tybor, J., Kasznicki, M., Konopka, L., Ceglarek, B., Komarnicki, M., Lewandowski, K., Hellmann, A., Moskwa, A., Dmoszynska, A., Sokolowska, B., Dwilewicz-Trojaczek, A., Tomaszewska, A., Sulek, K. Calbecka, M. (2004) Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. European Journal of Cancer, 40, 383 389.
30. Robertson, L.E., Pugh, W., O'Brien, S., Kantarjian, H., Hirsch-Ginsberg, C., Cork, A., McLaughlin, P., Cabanillas, F. Keating, M.J. (1993) Richter's syndrome: a report on 39 patients. Journal of Clinical Oncology, 11, 1985 1989.
31. Scadden, D.T. (2000) Epstein-Barr virus, the CNS, and AIDS-related lymphomas: as close as flame to smoke. Journal of Clinical Oncology, 18, 3323 3324.
32. Schollkopf, C., Rosendahl, D., Rostgaard, K., Pipper, C. Hjalgrim, H. (2007) Risk of second cancer after chronic lymphocytic leukemia. International Journal of Cancer, 121, 151 156.
33. Shanafelt, T.D., Geyer, S.M. Kay, N.E. (2004) Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood, 103, 1202 1210.
34. Shanafelt, T.D., Byrd, J.C., Call, T.G., Zent, C.S. Kay, N.E. (2006a) Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Annals of Internal Medicine, 145, 435 447.
35. Shanafelt, T.D., Witzig, T.E., Fink, S.R., Jenkins, R.B., Paternoster, S.F., Smoley, S.A., Stockero, K.J., Nast, D.M., Flynn, H.C., Tschumper, R.C., Geyer, S., Zent, C.S., Call, T.G., Jelinek, D.F., Kay, N.E. Dewald, G.W. (2006b) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 4634 4641.
36. Shields, D.J., Byrd, J.C., Abbondanzo, S.L., Lichy, J.H., Diehl, L.F. Aguilera, N.I. (1997) Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. Modern Pathology, 10, 1151 1159.
37. Tabuteau, S., Garidi, R., Fernandes, J., Vaida, I., Capiod, J., Legrand, S. Desablens, B. (2000) Fludarabine (FAMP) and risk of occurrence of Ricthter's syndrome among B-CLL. Blood, 96, (Abstract)295.
38. Thornton, P.D., Bellas, C., Santon, A., Shah, G., Pocock, C., Wotherspoon, A.C., Matutes, E. Catovsky, D. (2005) Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leukemia Research, 29, 389 395.
39. Timar, B., Fulop, Z., Csernus, B., Angster, C., Bognar, A., Szepesi, A., Kopper, L. Matolcsy, A. (2004) Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. Leukemia, 18, 326 330.
40. Travis, L.B., Curtis, R.E., Hankey, B.F. Fraumeni, Jr., J.F. (1992) Second cancers in patients with chronic lymphocytic leukemia. Journal of the National Cancer Institute, 84, 1422 1427.
41. Tsimberidou, A.M. Keating, M.J. (2005) Richter syndrome: biology, incidence, and therapeutic strategies. Cancer, 103, 216 228.
42. Tsimberidou, A.M. Keating, M.J. (2006) Richter's transformation in chronic lymphocytic leukemia. Seminars in Oncology, 33, 250 256.
43. Wiernik, P.H. (2004) Second neoplasms in patients with chronic lymphocytic leukemia. Current Treatment in Options Oncology, 5, 215 223.